Antimicrobial Resistance (AMR)
Phenotypic vs. Target-Based Screening​

Summary

The antimicrobial resistance (AMR) has been addressed already for several years with sustained promises of filling-in the pipeline of antibiotics with true innovative starting points and approaches.

The webinar intends to motivate a revision of the way we feed the research funnel with new ideas, new biology and new chemistry. In an open discussion, the scientists will share their experiences in antibiotic discovery and give their own view on the impact of the starting points and approaches on their achievements.

When

📆 July, 9th at 11:00AM (CEST)

Discussion Panel

Eric Bacqué

Eric Bacqué
PhD.

Evotec

VP Chemistry &
AMR Portfolio Coordinator

Santanu Datta

Santanu Datta PhD.

Bugworks

CSO &
Co-Founder

Marc Gitzinger

Marc Gitzinger PhD.

BioVersys

CEO &
Co-Founder

Moderator

Albert Palomer PhD.

Pharmacelera

Member of
the Board

Discussion Panel

Eric Bacqué

Eric Bacqué, PhD.

Evotec - VP Chemistry & AMR Portfolio Coordinator

Santanu Datta

Santanu Datta, PhD.

Bugworks - CSO & Co-Founder

Marc Gitzinger

Marc Gitzinger, PhD.

BioVersys - CEO & Co-Founder

Moderator

Albert Palomer, PhD.

Pharmacelera - Member of the Board

Webinar topics

  • Has phenotypic screening already explored the known chemical space?
    • In which manner can we explore new and diverse chemical space?
    • How to best design tailored-libraries for antibiotic discovery following the accumulated knowledge?
    • Are we effectively exploring new natural products chemistry? Accessing new sources vs. new genetic-based approaches.
  • Have target-based approaches met the promised expectations in antibiotic discovery?
    • Value of known antibacterial scaffolds with known molecular target.
    • Importance of new (validated) bacterial targets.
    • Turning IC50 into MIC values. Rules to penetrate the bacterial membrane.
  • Monotherapy, partial spectrum and broad spectrum. Unmet needs and market dynamics.